Apexigen, Inc. Common Stock (APGN)

APGN was delisted on the 22nd of August, 2023.

• Market cap: $9.57M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer.. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in clinical development, and also includes several preclinical stage immune-oncology programs.

Employees: 31